Q3 2024 Earnings Call Transcript November 6, 2024 Royalty Pharma plc misses on earnings expectations. Reported EPS is $0.918 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Adjusted Net Income Guidance: $1.275 billion to $1.35 billion. Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) reported strong growth across its commercial portfolio, with Xywav and Epidiolex posting ...

On Monday, Royalty Pharma plc (RPRX) stock saw a modest uptick, ending the day at $27.2 which represents a slight increase of $0.10 or 0.37% from the prior close of $27.1. The stock opened at $27.52 ...

My name is Abbie, and I’ll be your operator today. At this time, I would like to welcome everyone to the Jazz Pharmaceuticals Third Quarter 2024 Earnings Call. All lines have been placed on mute ...

Impax Asset Management Group plc raised its stake in shares of West Pharmaceutical Services, Inc. (NYSE:WST – Free Report) by 56.1% in the third quarter, according to its most recent 13F filing ...

Exscientia Plc (EXAI) has released an update. Exscientia Plc has announced a key amendment to its transaction agreement with Recursion ...

Good day and thank you for standing by. Welcome to Kiniksa Pharmaceuticals Third Quarter 2024 Earnings Conference Call. At this time all participants are in a listen-only mode. Please be advised ...

London, United Kingdom – Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical group, today provides an update on current trading.

Proceeds expected to support the upcoming planned launches and fund the continued development of Niktimvo and revumenibExpected to fund Syndax through profitability; proforma cash approaching $800 mil ...